GlassScriptPhysician profile
Massoud Saberinia
NPI 1962437079
$7,529.41
in general payments reported to CMS, 2019-2025
39 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $271 · 2021: $767 · 2022: $1,389 · 2023: $1,802 · 2024: $1,346 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,574 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,573.64 |
| Education | $116.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,174.64 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,243.18 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $838.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $479.05 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $332.40 | 2021-2025 | Unithroid |
| Amgen INC. | $323.32 | 2022-2025 | Tepezza, Evenity, Repatha |
| Abbvie INC. | $216.62 | 2024-2025 | |
| Insulet Corporation | $207.02 | 2020-2025 | Omnipod |
| Beta Bionics, INC. | $165.15 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ibsa Pharma INC. | $125.89 | 2021-2025 | Tirosint, Licart, Tirosint |
| Merck Sharp & Dohme LLC | $121.62 | 2021-2023 | Steglatro |
| Medtronic, INC. | $117.29 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Medtronic Minimed, INC. | $112.34 | 2019 | |
| Tandem Diabetes Care, INC. | $110.93 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $88.93 | 2023-2024 | Gvoke Hypopen |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $87.19 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $69.31 | 2022-2024 | |
| Amarin Pharma, INC. | $61.82 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $59.26 | 2024-2025 | Yorvipath |
| Amphastar Pharmaceuticals, INC. | $53.87 | 2023-2025 | Baqsimi |
| Embecta Corp. | $47.96 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Mannkind Corporation | $43.08 | 2022 | |
| Corcept Therapeutics | $40.40 | 2025 | Korlym |
| Esperion Therapeutics, INC. | $40.15 | 2024 | Nexletol |
| Abbott Laboratories | $39.02 | 2022-2024 | Freestyle Libre 3 |
| Antares Pharma, INC. | $36.96 | 2023 | Nocdurna, Tlando, Xyosted |
| Lifescan, INC. | $31.61 | 2023 | |
| Sequel Med Tech, LLC | $30.32 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $23.92 | 2025 | NP Thyroid 60 |
| Companion Medical, INC. | $23.60 | 2019 | |
| Ascensia Diabetes Care US INC. | $22.99 | 2023 | |
| Horizon Therapeutics Plc | $22.90 | 2023 | Tepezza |
| Recordati_rare_diseases_inc. | $21.82 | 2023 | Signifor Lar, Isturisa |
| Azurity Pharmaceuticals, INC. | $21.76 | 2025 | Azmiro |
| Allergan, INC. | $21.17 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.41 | 2025 | |
| Pfizer INC. | $19.58 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $17.46 | 2021 | |
| Clarus Therapeutics INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Massoud Saberinia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.